Commonwealth Equity Services
RNTX

Commonwealth Equity Services’s Rein Therapeutics RNTX Stock Holding History

Commonwealth Equity Services’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-540
Closed -$6K – 3812
2021
Q4 		$6K Sell
540
-10
-2% -$155 ﹤0.01% 3639
2021
Q3 		$11K Hold
550
– – ﹤0.01% 3562
2021
Q2 		$13K Hold
550
– – ﹤0.01% 3510
2021
Q1 		$15K Buy
+550
New +$18.8K ﹤0.01% 3387

Other funds holding RNTX

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KL
KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCA
Taconic Capital Advisors New York $229M AUM 110.07% 1-Year Est. Return

Commonwealth Equity Services's RNTX Position: Q1 2022 in Review

Commonwealth Equity Services sold out of Rein Therapeutics (RNTX) in Q1 2022, closing a stake of 540 shares — an estimated $6K sold.

Commonwealth Equity Services first reported a position in RNTX in Q1 2021 and held it in 4 quarters. The position peaked at $15K in Q1 2021. 42 funds tracked by Wall St. Rank hold RNTX as of Q1 2022.

  • Commonwealth Equity Services reported no remaining Rein Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Commonwealth Equity Services sold 540 Rein Therapeutics shares in Q1 2022, an estimated $6K.
  • Commonwealth Equity Services first reported a position in Rein Therapeutics in Q1 2021 and held it in 4 quarters.
  • Commonwealth Equity Services's Rein Therapeutics position peaked at $15K in Q1 2021.
  • 42 funds tracked by Wall St. Rank held Rein Therapeutics as of Q1 2022.

Based on Commonwealth Equity Services's 13F filing for Q1 2022, filed 4 May 2022.